Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | CASP9 | P55211 | 2/20 | 0.59 |
| ▸ | CASP6 | P55212 | 2/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26071633 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29384302 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24213871 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL14646635 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29043505 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL30376490 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL8353502 | 0.90 | CASP3 (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL10084325 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23268995 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577273-B2 | Small molecule modulators of gut bacterial bile acid metabolism | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-17 | — | — | US | disclosed |
| CN-114641280-B | Small molecule regulator of intestinal bacterial bile acid metabolism | 哈佛大学的校长及成员们 | 2025-05-27 | — | — | CN | disclosed |
| US-20250161334-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2025-05-22 | — | — | US | disclosed |
| US-12226478-B2 | Method of treating, reducing, or alleviating a medical condition in a patient | PEYMAN GHOLAM A (US) | 2025-02-18 | — | — | US | disclosed |
| US-12048750-B2 | Tissue-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240208898-A1 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4313013-A2 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | Dana-Farber Cancer Institute, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279629-A | Enamine N-oxide: synthesis and use in hypoxia responsive prodrugs and imaging agents | 达纳－法伯癌症研究所公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230338520-A1 | Method Of Treating, Reducing, Or Alleviating A Medical Condition In A Patient | PEYMAN GHOLAM A (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410956-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-12 | — | — | US | disclosed |
| WO-2008056897-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008056898-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008016239-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-02-07 | — | — | WO | disclosed |
| WO-2006090997-A1 | ISOXAZOLINE DERIVATIVE AND NOVEL PROCESS FOR ITS PREPARATION | LG LIFE SCIENCES LTD. (KR) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006033551-A1 | CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE | LG LIFE SCIENCES LTD. (KR) | 2006-03-30 | — | — | WO | disclosed |
| EP-1628674-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | Cytovia, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2003068242-A1 | PHOSPHOLIPIDS AS CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048750-B2 | Tissue-homing peptide conjugates and methods of use thereof | CXCL12, CCL2, CD44 | CASP3 2361/4885CASP7 1922/4885CASP9 1442/4885 |
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP7 10/4885CASP9 12/4885 |
| US-12577273-B2 | Small molecule modulators of gut bacterial bile acid metabolism | NR1H4, GPBAR1, FABP2 | CASP3 2200/4885CASP7 2325/4885CASP9 1846/4885 |
| US-20240208898-A1 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | ENO1, HIF1A, HIF1AN | CASP3 1062/4885CASP7 1525/4885CASP9 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.